Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
about
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An OverviewThe Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid ArthritisFuture perspectives in target-specific immunotherapies of myasthenia gravisThe Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Distinct Elements in the Proteasomal β5 Subunit Propeptide Required for Autocatalytic Processing and Proteasome AssemblyBortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: A case report and review of the literature.Old game, new players: Linking classical theories to new trends in transplant immunology.Emerging role of immunoproteasomes in pathophysiology.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Severe refractory CIDP: a case series of 10 patients treated with bortezomib.RNAi Screen and Proteomics Reveal NXF1 as a Novel Regulator of IRF5 Signaling.Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.(Immuno)proteasomes as therapeutic target in acute leukemia.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren's syndrome.Of Mice and Men: Proteasome's Role in LPS-Induced Inflammation and Tolerance.Targeting B Cells and Plasma Cells in Autoimmune Diseases.Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases
P2860
Q26738752-2C9D97D8-398E-47AD-89A0-D0F95E1DB59AQ26774681-55AF3E1D-22D4-4A50-9047-146FEEAE3ED2Q26776225-3B19FEDC-0469-4BFF-83A9-687D4A51D0FAQ33559343-49FDCF22-68A8-4110-8EB0-A1BCE27F1457Q36484383-68B0A083-3EA5-4E44-81C2-EF1BE983BA98Q36489345-8F02CCC6-513C-4024-9490-01031D3EDBD8Q37552226-AA5805FD-8780-4646-BE8B-D2F38CC9CAE8Q37662989-56E510B2-24E1-4B78-9323-EA1D62430A7FQ38837519-82F00BFE-5FB8-4BA6-95EC-298862E8839DQ39234159-A14DA03B-4422-417D-A467-5EB8B0EE0B31Q40081746-22CDAA0B-BD16-4356-B364-80EFA2C3A382Q40173963-4A941B44-A7C6-47CD-A871-41A3CC6DEBCAQ41657907-A29B05B9-7F25-4310-ABC1-B6446CD0C89AQ41996298-8789EBC7-0AA8-4FC9-B1C3-15BBFC92CEE8Q47122756-7D3BD2B6-969F-4B60-862D-0418B7E8C9F2Q47131929-BDB77C6C-E230-434A-9D4E-5FC00CED6333Q47292306-B3490C18-6E54-4FB8-9824-30409514044FQ48727596-1CE6DB43-6C01-477E-B3BF-EBAE30A5929DQ53720678-5FA03245-AE44-4CFB-8158-2630BDB16D43Q55234556-A94F9709-1B22-4F40-B8BF-02AB68A7B961Q55407957-0BAFDB61-62F6-4E10-8D32-35F6B452270DQ58051874-7F790A42-78B3-4FD1-9CBD-210FAEBC1CEB
P2860
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
@en
type
label
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
@en
prefLabel
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
@en
P2093
P2860
P1476
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
@en
P2093
Gerrit Jansen
Rik J Scheper
Sue Ellen Verbrugge
Tanja D de Gruijl
Willem F Lems
P2860
P2888
P356
10.1186/S13075-015-0529-1
P5008
P577
2015-01-28T00:00:00Z
P5875
P6179
1031955826